A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or o
详细信息 查看全文
- 作者：Mundorf ; Thomas K. ; Ogawa ; Takahiro ; Naka ; Hiroaki ; Novack ; Gary D. ; Stephens Crockett ; R.
- 关键词：timolol ; glaucoma ; intraocular pressure ; sorbate ; controlled trial
- 刊名：Clinical Therapeutics
- 出版年：2004
- 出版时间：April, 2004
- 年：2004
- 卷：26
- 期：4
- 页码：541-551
- 全文大小：121 K
文摘
Background: Timolol maleate, a nonselective β-adrenoceptor antagonist applied topically to the eye as a solution, is well known for its ocular hypotensive efficacy. A gellan formulation of timolol maleate is given once daily and has been shown to be as effective as timolol maleate solution, but is associated with ocular symptoms that may limit its utility. A new timolol maleate solution has been formulated that contains potassium sorbate (timolol-LA [TLA; Istalol®]) to enhance the ocular bioavailability of timolol instilled into the eye, as well as half the benzalkonium chloride preservative found in timolol maleate.